https://www.selleckchem.com/products/ki20227.html
Coronavirus disease 2019 (COVID-19) is associated with increased risk of acute ischemic stroke (AIS), however, there is a paucity of data regarding outcomes after administration of intravenous tissue plasminogen activator (IV tPA) for stroke in patients with COVID-19. We present a multicenter case series from 9 centers in the United States of patients with acute neurological deficits consistent with AIS and COVID-19 who were treated with IV tPA. We identified 13 patients (mean age 62 (±9.8) years, 9 (69.2%) male). All received IV tPA an
Like
Comment
Share
